Synairgen recently reported positive data from its ongoing work in partnership with Pharmaxis to develop a lysyl oxidase type 2 enzyme (LOXL2) inhibitor as a new treatment for idiopathic pulmonary fibrosis (IPF). Synairgen is ... Read more